
LENSAR Inc (LNSR) Stock Forecast & Price Target
LENSAR Inc (LNSR) Analyst Ratings
Bulls say
LENSAR is making significant strides in the ophthalmic medical device market with their femtosecond laser system for cataract surgery. With strong financials and a growing install base, they are well-positioned for continued success. The failed acquisition by Alcon may provide an opportunity for other companies to respond and potentially lead to increased competition in the market. However, we believe that LENSAR's innovative technology and focus on recurring revenue will drive future growth and justify a higher valuation compared to its peers.
Bears say
LENSAR is facing significant challenges in the market and its future revenue streams due to lower growth projections and higher operating spend. With flat revenue in FY26 and further decline in FY27 and FY28, their ALLY pricing changes and thinner margins will make it difficult for them to remain competitive in the ophthalmic industry. Despite a strong initial performance, the terminated acquisition by ALC and the need for a priority credit line agreement to stay afloat raises concerns about their ability to continue operations in the long term.
This aggregate rating is based on analysts' research of LENSAR Inc and is not a guaranteed prediction by Public.com or investment advice.
LENSAR Inc (LNSR) Analyst Forecast & Price Prediction
Start investing in LENSAR Inc (LNSR)
Order type
Buy in
Order amount
Est. shares
0 shares